Zoi Tsimtsiou

Prof. Dr. Zoi Tsimtsiou

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Medical Education
Verified
Journal Article
Closed access
PDF file
ZTZoi Tsimtsiou
Zoi Tsimtsiou
OKOlga Kerasidou
Olga Kerasidou
NENikolaos Efstathiou
Nikolaos Efstathiou
SPStamatis Papaharitou
Stamatis Papaharitou
KHKonstantinos Hatzimouratidis
Konstantinos Hatzimouratidis
DHDimitris Hatzichristou
Dimitris Hatzichristou

4 December 2013 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
ZTZoi Tsimtsiou
Zoi Tsimtsiou
AHAnna-Bettina Haidich
Anna-Bettina Haidich
SKStamatia Kokkali
Stamatia Kokkali
TDTheodoros Dardavesis
Theodoros Dardavesis
KYKimberly S. Young
Kimberly S. Young
MAMalamatenia Arvanitidou
Malamatenia Arvanitidou

19 June 2024 in Life
Verified
Journal Article
Open access
PDF file
LKLaskarina Katsika
Laskarina Katsika
EBEirini Boureka
Eirini Boureka
IKIoannis Kalogiannidis
Ioannis Kalogiannidis
Ioannis TsakiridisIoannis Tsakiridis
Ioannis Tsakiridis
ITIlias Tirodimos
Ilias Tirodimos
TDThemistoklis Dagklis
Themistoklis Dagklis
Breast cancer is the most common malignancy diagnosed in the female population worldwide and the leading cause of death among perimenopausal women. Screening is essential, since earlier detection in combination with improvements in breast cancer treatment can reduce the associated mortality. The aim of this study was to review and compare the recommendations from published guidelines on breast cancer screening. A total of 14 guidelines on breast cancer screening issued between 2014 and 2022 were identified. A descriptive review of relevant guidelines by the World Health Organization (WHO), the U.S. Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), the National Comprehensive Cancer Network (NCCN), the American College of Obstetricians and Gynecologists (ACOG), the American Society of Breast Surgeons (ASBrS), the American College of Radiology (ACR), the Task Force on Preventive Health Care (CTFPHC), the European Commission Initiative on Breast Cancer (ECIBC), the European Society for Medical Oncology (ESMO), the Royal Australian College of General Practitioners (RACGP) and the Japanese Journal of Clinical Oncology (JJCO) for women both at average and high-risk was carried out. There is a consensus among all the reviewed guidelines that mammography is the gold standard screening modality for average-risk women. For this risk group, most of the guidelines suggest annual or biennial mammographic screening at 40–74 years, while screening should particularly focus at 50–69 years. Most of the guidelines suggest that the age limit to stop screening should be determined based on the women’s health status and life expectancy. For women at high-risk, most guidelines recommend the use of annual mammography or magnetic resonance imaging, while the starting age should be earlier than the average-risk group, depending on the risk factor. There is discrepancy among the recommendations regarding the age at onset of screening in the various high-risk categories. The development of consistent international practice protocols for the most appropriate breast cancer screening programs seems of major importance to reduce mortality rates and safely guide everyday clinical practice.

11 February 2015 in Academic Psychiatry
Verified
Journal Article
Closed access
PDF file
ZTZoi Tsimtsiou
Zoi Tsimtsiou
AHAnna-Bettina Haidich
Anna-Bettina Haidich
DSDimitris Spachos
Dimitris Spachos
SKStamatia Kokkali
Stamatia Kokkali
PBPanagiotis Bamidis
Panagiotis Bamidis
MAMalamatenia Arvanitidou
Malamatenia Arvanitidou

22 April 2017 in International Journal of Adolescent Medicine and Health
Verified
Journal Article
Closed access
PDF file
ZTZoi Tsimtsiou
Zoi Tsimtsiou
AHAnna-Bettina Haidich
Anna-Bettina Haidich
ADAnastasios Drontsos
Anastasios Drontsos
FDFotini Dantsi
Fotini Dantsi
ZSZafiria Sekeri
Zafiria Sekeri
MAMalamatenia Arvanitidou
Malamatenia Arvanitidou
Purpose: This study investigated the prevalence of Internet addiction (IA) and cyberbullying and examined profiles of adolescents with increased risk to develop pathological behaviors. Methods: In this cross-sectional, school-based study, 8053 students of 30 middle and 21 high schools (12–18 years old) were invited to participate, based on a multistage stratified random sampling technique. The Internet aiddiction test (IAT) was used along with information on socio-demographics, Internet activities and cyberbullying experience. Results: Five thousand five hundred and ninety students participated (response rate 69.4%). Pathological Internet use (IAT ≥50) was found in 526 (10.1%), while 403 (7.3%) experienced cyberbullying as victims and 367 (6.6%) as perpetrators during the last year. In multivariable models, the odds of IA increased with online hours on mobile phones and Internet use during weekends, Internet café visits, chatrooms usage and engagement in cyberbullying. Cyberbullying victims were more likely to be older, female, Facebook and chatrooms users, while perpetrators were more likely to be male, older Internet users and fans of pornographic sites. A perpetrator was significantly more likely to have also been a victim [odds ratio (OR) = 5.51, confidence interval (CI): 3.92–7.74]. Hours of daily Internet use on a mobile phone was independently associated with IA and cyberbullying (OR) 1.41, 95% CI 1.30, 1.53 and OR 1.11, 95% CI 1.01, 1.21, respectively. Conclusions: Cyberbullying is associated with IA and the hours spent online on a mobile phone affected both conditions. The increasing Internet access through mobile phones or other devices should be accompanied by the appropriate education of both parents and adolescents on safe Internet use.

20 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EZEvgenia Zampaoglou
Evgenia Zampaoglou
EBEirini Boureka
Eirini Boureka
EGEvdoxia Gounari
Evdoxia Gounari
PLPolyxeni-Natalia Liasidi
Polyxeni-Natalia Liasidi
IKIoannis Kalogiannidis
Ioannis Kalogiannidis
Themistoklis DagklisThemistoklis Dagklis
Themistoklis Dagklis
Cervical cancer remains one of the main causes of female mortality, especially in middle- and low-income countries, despite efforts towards the implementation of global vaccination against human papillomavirus (HPV). The aim of this study was to review and compare the most recently published international guidelines providing recommendations on cervical cancer screening strategies among average and high-risk women. Thus, a comparative review of guidelines by the US Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), the World Health Organization (WHO), the Canadian Task Force on Preventive Health Care (CTFPHC), the Cancer Council Australia (CCA), and the European Guidelines (EG) was conducted. There is an overall agreement regarding the suggestions made for women younger than 21 and those older than 65, with all guidelines stating against routine screening, with the exceptions of CTFPHC and CCA that expand the age group to up to 70 and 75 years, respectively. Continuation of screening in older women is also suggested in those with a history of a precancerous lesion and those with inadequate screening. Most guidelines recommend routine screening at 30–65 years, while the WHO advises that screening should be prioritized at 30–49 years. HPV DNA testing is the method of choice recommended by most guidelines, followed by cytology as an alternative, except for CTFPHC, which refers to cytology only, with self-sampling being an acceptable method by most medical societies. Agreements exist regarding recommendations for specific groups, such as women with a history of total hysterectomy for benign reasons, women with a complete vaccination against HPV, individuals from the lesbian, gay, bisexual, transgender, and queer communities and women with multiple sexual partners or early initiation of sexual activity. On the other hand, the age group of 21–29 is addressed differently by the reviewed guidelines, while differentiations also occur in the screening strategies in cases of abnormal screening results, in women with immunodeficiency, those with in utero exposure to diethylstilbestrole and pregnant women. The development of consistent practice protocols for the most appropriate cervical cancer screening programs seems to be of major importance to reduce mortality rates and safely guide everyday clinical practice.